{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.0","value":"9.42"},{"groupId":"OG001","spread":"3.8","value":"11.95"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Serum IgG levels against the PVC serotype were measured by ELISA","dispersionType":"Standard Error","groups":[{"description":"Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).\n\npneumococcal polyvalent vaccine: Given intramuscularly\n\nlenalidomide: Given orally","id":"OG000","title":"Vaccine Started 14 Days Prior to Lenalidomide"},{"description":"Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).\n\npneumococcal polyvalent vaccine: Given intramuscularly\n\nlenalidomide: Given orally","id":"OG001","title":"Vaccine Started 45 Days After Lenalidomide"}],"paramType":"MEAN","populationDescription":"Patients who showed evidence of disease progression while on study were not included in the analysis.","reportingStatus":"POSTED","timeFrame":"basline and 8 weeks after second vaccination","title":"14F Antibody Response to Prevnar Vaccine in Peripheral Blood","type":"PRIMARY","unitOfMeasure":"fold change"}